BridgeMD
REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study.
EU CTIS ID: 2023-509026-21-00
What this study is testing
1. Describe the proportion of patients that achieved clinical remission at 12 months, in the principal stratum of patients’ adherent to NUCALA
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Adults aged 18 years or over
- 2. Participant has a confirmed asthma diagnosis with physician decision to initiate treatment with NUCALA
- 3. Participants with ≥60% predicted FEV1 and ≤4 exacerbations per year, as confirmed by the physician.
- 4. Written informed consent.
You likely can't join if
- 1. Investigator concerns about participant’s willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare)
- 2. Any NUCALA use in the 6 months prior to enrollment.
- 3. Participants currently on maintenance oral corticosteroids (mOCS) or intramuscular corticosteroids.
- 4. Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment.
- 5. Participating in an interventional study with a treatment intervention.
- 6. Other clinically significant respiratory conditions (e.g., bronchiectasis, pulmonary fibrosis).
See the full eligibility criteria
- 1. Adults aged 18 years or over
- 2. Participant has a confirmed asthma diagnosis with physician decision to initiate treatment with NUCALA
- 3. Participants with ≥60% predicted FEV1 and ≤4 exacerbations per year, as confirmed by the physician.
- 4. Written informed consent.
- 1. Investigator concerns about participant’s willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare)
- 2. Any NUCALA use in the 6 months prior to enrollment.
- 3. Participants currently on maintenance oral corticosteroids (mOCS) or intramuscular corticosteroids.
- 4. Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment.
- 5. Participating in an interventional study with a treatment intervention.
- 6. Other clinically significant respiratory conditions (e.g., bronchiectasis, pulmonary fibrosis).
- 7. Current smokers.
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- United Kingdom
- Canada
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; United Kingdom; Canada; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.